Literature DB >> 12789290

Apoptosis and melanoma chemoresistance.

María S Soengas1, Scott W Lowe.   

Abstract

Melanoma is the most aggressive form of skin cancer and is notoriously resistant to all current modalities of cancer therapy. A large set of genetic, functional and biochemical studies suggest that melanoma cells become 'bullet proof' against a variety of chemotherapeutic drugs by exploiting their intrinsic resistance to apoptosis and by reprogramming their proliferation and survival pathways during melanoma progression. In recent years, the identification of molecules involved in the regulation and execution of apoptosis, and their alteration in melanoma, have provided new insights into the molecular basis for melanoma chemoresistance. With this knowledge in hand, the challenge is now to devise strategies potent enough to compensate or bypass these cell death defects and improve the actual poor prognosis of patients at late stages of the disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12789290     DOI: 10.1038/sj.onc.1206454

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  242 in total

1.  Selenium-containing histone deacetylase inhibitors for melanoma management.

Authors:  Raghavendra Gowda; Subbarao V Madhunapantula; Dhimant Desai; Shantu Amin; Gavin P Robertson
Journal:  Cancer Biol Ther       Date:  2012-06-06       Impact factor: 4.742

Review 2.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

3.  1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP) facilitates curcumin-induced melanoma cell apoptosis by enhancing ceramide accumulation, JNK activation, and inhibiting PI3K/AKT activation.

Authors:  Teng Yu; Jinchao Li; Ying Qiu; Hui Sun
Journal:  Mol Cell Biochem       Date:  2011-09-29       Impact factor: 3.396

4.  Targeting of eEF1A with Amaryllidaceae isocarbostyrils as a strategy to combat melanomas.

Authors:  Gwendoline Van Goietsenoven; Jenna Hutton; Jean-Paul Becker; Benjamin Lallemand; Francis Robert; Florence Lefranc; Christine Pirker; Guy Vandenbussche; Pierre Van Antwerpen; Antonio Evidente; Walter Berger; Martine Prévost; Jerry Pelletier; Robert Kiss; Terri Goss Kinzy; Alexander Kornienko; Véronique Mathieu
Journal:  FASEB J       Date:  2010-07-19       Impact factor: 5.191

5.  Inhibition of experimental metastasis by targeting the HUIV26 cryptic epitope in collagen.

Authors:  Jennifer M Roth; Maresa Caunt; Alexandra Cretu; Abebe Akalu; Desiree Policarpio; Xiaolu Li; Paul Gagne; Silvia Formenti; Peter C Brooks
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

6.  A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma.

Authors:  Karl D Lewis; John A Thompson; Jeffrey S Weber; William A Robinson; Steven O'Day; Jose Lutzky; Sewa S Legha; Simon Floret; Francis Ruvuna; Rene Gonzalez
Journal:  Invest New Drugs       Date:  2006-01       Impact factor: 3.850

7.  Enhancement of the proapoptotic properties of newcastle disease virus promotes tumor remission in syngeneic murine cancer models.

Authors:  Sara Cuadrado-Castano; Juan Ayllon; Mena Mansour; Janis de la Iglesia-Vicente; Stefan Jordan; Shashank Tripathi; Adolfo García-Sastre; Enrique Villar
Journal:  Mol Cancer Ther       Date:  2015-03-11       Impact factor: 6.261

8.  Artemisinin reduces human melanoma cell migration by down-regulating alpha V beta 3 integrin and reducing metalloproteinase 2 production.

Authors:  Elisabetta Buommino; Adone Baroni; Nunzia Canozo; Marcella Petrazzuolo; Rosario Nicoletti; Antonio Vozza; Maria Antonietta Tufano
Journal:  Invest New Drugs       Date:  2008-10-28       Impact factor: 3.850

9.  SLUG silencing increases radiosensitivity of melanoma cells in vitro.

Authors:  Chiara Arienti; Anna Tesei; Silvia Carloni; Paola Ulivi; Antonino Romeo; Giulia Ghigi; Enrico Menghi; Anna Sarnelli; Elisabetta Parisi; Rosella Silvestrini; Wainer Zoli
Journal:  Cell Oncol (Dordr)       Date:  2012-12-19       Impact factor: 6.730

10.  RhoJ modulates melanoma invasion by altering actin cytoskeletal dynamics.

Authors:  Hsiang Ho; Amelia Soto Hopkin; Rubina Kapadia; Priya Vasudeva; Jonathan Schilling; Anand K Ganesan
Journal:  Pigment Cell Melanoma Res       Date:  2013-01-07       Impact factor: 4.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.